Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
What Lupin files
- Updates148
- Others107
- Investor Meet34
- Important19
- Board Meeting8
- PPTs8
Lupin's subsidiary VISUfarma inked an exclusive deal with Visus Therapeutics to commercialize YUVEZZI™ for presbyopia in Europe. This strengthens Lupin’s ophthalmology portfolio and expands its specialty business, targeting long-term growth. The deal involves up to €7.5 Cr plus royalties.
Lupin significantly advanced sustainability, cutting Scope 1&2 GHG emissions by 41% and Scope 3 intensity by 35%. Renewable energy hit 51%. The company invested 2,063.1 Cr in R&D and 38.7 Cr in Capex. Zero Class 1 recalls were maintained, and a Platinum Rating for human rights achieved. 9 voluntary product...
Lupin's Pithampur Unit-2 facility received an 'Official Action Indicated' (OAI) status from the US FDA. The company is actively working to resolve compliance issues identified during the prior inspection.
Lupin's Chhatrapati Sambhajinagar (Aurangabad) facility recently underwent a US FDA pre-approval inspection, concluding with two observations. The company plans to address these promptly, reaffirming its commitment to CGMP quality standards.
Lupin's latest report highlights a significant operational focus on R&D, with increased investments. The company achieved notable gains in sustainability, reducing GHG emissions, boosting renewable energy use, and implementing Zero Liquid Discharge at six plants. Financial efficiency improved with faster accounts payable. However, operational challenges emerged with 13 voluntary product...